SEOM Clinical Guideline for bone metastases from solid tumours (2016).

In postmenopausal women, there were highly significant reductions with the addition of bisphosphonates at 10 years for bone recurrence (6.6 vs 8.8%, p = 0.0002) and for breast cancer mortality (14.7 vs 18.0%, p = 0.002).

also in 132,142 other papers

For all patients, there were borderline significant reductions with the addition of bisphosphonates at 10 years for distant recurrence (20.4 vs 21.8%, p = 0.03), bone recurrence (7.8 vs 9.0%, p = 0.004), breast cancer mortality (16.6 vs 18.4%, p = 0.04), and all-cause mortality (20.8 vs 22.3%, 2 p = 0.06).

also in 11,409 other papers